MYO1D

Across TCGA pan-cancer cohorts, MYO1D RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of MYO1D’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where MYO1D RNA is repressed in tumor relative to normal tissue. In most cancer types MYO1D is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

KIRC, HNSC, and KICH are the cancer types where MYO1D tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MYO1D RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	III,IV	−0.706	<.001	10	view →
HNSC	All	All	+0.538	<.001	8	view →
KICH	All	III,IV	−1.151	<.001	7	view →
READ	All	All	−1.071	<.001	7	view →
BRCA	All	III,IV	+0.954	<.001	6	view →
BLCA	Female	All	+0.636	.006	6	view →
COAD	Female	II,III,IV	−1.150	<.001	5	view →
STAD	All	II,III,IV	+0.844	.005	5	view →
CHOL	Male	All	+2.090	<.001	4	view →
LIHC	Female	All	+1.112	<.001	4	view →
LUAD	All	II,III,IV	+0.420	.019	4	view →
PRAD	All	All	+0.539	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

MYO1D–KIRC

Open the KIRC breakdown →